Illumina & Tempus collaborate to drive future of precision medicine through genomic AI innovation: San Diego Saturday, April 19, 2025, 12:00 Hrs [IST] Illumina Inc. and Tempus AI, ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel ...

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance ...

The global healthtech market is experiencing rapid growth due to increasing health awareness and preventive care and the surge in the ageing popul ...

BofA lowered the firm’s price target on Tempus AI (TEM) to $48 from $60 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Nancy Pelosi’s only profitable 2025 stock, Tempus AI is in radar after insider trading filings revealed over $1.34 million in ...